Indivior PLC - Asset Resilience Ratio
Indivior PLC (INDV) has an Asset Resilience Ratio of 0.07% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Indivior PLC to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how Indivior PLC's Asset Resilience Ratio has changed over time. See INDV equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Indivior PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see INDV market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX1.00 Million | 0.07% |
| Total Liquid Assets | GBX1.00 Million | 0.07% |
Asset Resilience Insights
- Limited Liquidity: Indivior PLC maintains only 0.07% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Indivior PLC Industry Peers by Asset Resilience Ratio
Compare Indivior PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Eris Lifesciences Limited
NSE:ERIS |
Drug Manufacturers - Specialty & Generic | 0.58% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Lotus Pharmaceutical Co Ltd
TW:1795 |
Drug Manufacturers - Specialty & Generic | 0.49% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC |
Drug Manufacturers - Specialty & Generic | 0.64% |
Annual Asset Resilience Ratio for Indivior PLC (2022–2024)
The table below shows the annual Asset Resilience Ratio data for Indivior PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.08% | GBX1.00 Million ≈ $121.67 |
GBX1.32 Billion ≈ $160.48K |
-4.73pp |
| 2023-12-31 | 4.81% | GBX94.00 Million ≈ $11.44K |
GBX1.95 Billion ≈ $237.75K |
-1.92pp |
| 2022-12-31 | 6.73% | GBX119.00 Million ≈ $14.48K |
GBX1.77 Billion ≈ $215.24K |
-- |
About Indivior PLC
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more